You are viewing an expired study

This study is not currently recruiting Study Participants on If you would like to find active studies please browse nearby listings below.

Click here to view additional nearby studies or search for clinical trials.

Salt Lake City, Utah 84112

  • Neoplasms


The Kanglaite Injection (KLT)is a novel broad spectrum anti-cancer injection produced from traditional Chinese medicinal herbs (the Coix Seed). It was approved in China in 1995 and has become the most popular anti-cancer drug in China. In June of 2001, the Phase I study of KLT commenced at the Huntsman Cancer Institute in Salt Lake City, Utah, with the objectives of 1) To determine the maximum tolerated dose (MTD) and the safety profile of KLT in patients with refractory solid tumors; 2) To determine the pharmacokinetics of KLT in patients with refractory solid tumors; and 3) To gather preliminary efficacy data. The method of testing is open-label, sequential cohort, dose-escalation study.


- Patients with histological evidence of malignancy that has become refractory to standard therapy, or for whom effective standard therapy does not exist. - Patients with an estimated life-expectancy of at least 3 months - Patients with a Karnofsky Performance Score of at least 60% - Patients with no history of congestive heart failure (CHF), and normal ejection fraction by echocardiography - Patients with adequate renal and hepatic function - Patients with adequate bone marrow status



Primary Contact:

Principal Investigator
Richard H Wheeler, M.D.
Huntsman Cancer Institute

Backup Contact:


Location Contact:

Salt Lake City, Utah 84112
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source:

Date Processed: April 03, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on The form below is not enabled.